Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Accell TBM (Total Bone Matrix) is a demineralized bone matrix (DBM) product used as a bone graft substitute in orthopedic and spinal procedures. Originally developed by IsoTis Inc. and currently marketed by Orthofix (following its association with Integra LifeSciences and SeaSpine), it is composed of demineralized human bone. The product is unique for being a moldable DBM graft created through a proprietary process that does not require an inert carrier or plasticizer, ensuring the entire matrix is osteoconductive with osteoinductive potential. It is primarily indicated as a bone graft extender or bone void filler in the spine, extremities, and pelvis, often serving as an alternative to autologous bone harvesting from the iliac crest.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Accell TBM.